Scheduled Maintenance
We have scheduled some maintenance on Saturday 4th of May 2024 starting from 10AM CEST and could last for 2 hours. During this maintenance we are expecting our website to be unavailable or not fully functional.
NYXOAH SA (NYXH)
BE0974358906 - Common Stock
NYXH gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 192 industry peers in the Health Care Equipment & Supplies industry. NYXH scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NYXH is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
NYXH had negative earnings in the past year.
In the past year NYXH has reported a negative cash flow from operations.
NYXH had negative earnings in each of the past 5 years.
In the past 5 years NYXH always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -34.81%, NYXH is in line with its industry, outperforming 41.67% of the companies in the same industry.
With a Return On Equity value of -44.09%, NYXH perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -34.81% | ||
| ROE | -44.09% | ||
| ROIC | N/A |
ROA(3y)-24.12%
ROA(5y)-27.74%
ROE(3y)-29.54%
ROE(5y)-65.78%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 61.91%, NYXH is in line with its industry, outperforming 59.90% of the companies in the same industry.
NYXH's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for NYXH so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 61.91% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.08%
GM growth 5YN/A
2. Health
2.1 Basic Checks
NYXH does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NYXH has more shares outstanding
NYXH has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, NYXH has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 3.74 indicates that NYXH is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 3.74, NYXH is doing good in the industry, outperforming 71.35% of the companies in the same industry.
A Debt/Equity ratio of 0.12 indicates that NYXH is not too dependend on debt financing.
NYXH has a Debt to Equity ratio of 0.12. This is comparable to the rest of the industry: NYXH outperforms 56.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.74 |
ROIC/WACCN/A
WACC7.27%
2.3 Liquidity
A Current Ratio of 4.73 indicates that NYXH has no problem at all paying its short term obligations.
The Current ratio of NYXH (4.73) is better than 65.63% of its industry peers.
A Quick Ratio of 4.50 indicates that NYXH has no problem at all paying its short term obligations.
The Quick ratio of NYXH (4.50) is better than 72.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.73 | ||
| Quick Ratio | 4.5 |
3. Growth
3.1 Past
NYXH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -29.20%.
The Revenue has grown by 40.99% in the past year. This is a very strong growth!
The Revenue has been growing by 297.94% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-29.2%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q25.49%
Revenue 1Y (TTM)40.99%
Revenue growth 3Y297.94%
Revenue growth 5YN/A
Revenue growth Q2Q39.56%
3.2 Future
The Earnings Per Share is expected to grow by 1.95% on average over the next years.
Based on estimates for the next years, NYXH will show a very strong growth in Revenue. The Revenue will grow by 119.78% on average per year.
EPS Next Y-18.59%
EPS Next 2Y-9.01%
EPS Next 3Y1.95%
EPS Next 5YN/A
Revenue Next Year114.68%
Revenue Next 2Y185.62%
Revenue Next 3Y167.8%
Revenue Next 5Y119.78%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
NYXH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NYXH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.01%
EPS Next 3Y1.95%
5. Dividend
5.1 Amount
NYXH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYXOAH SA
NASDAQ:NYXH (5/3/2024, 7:09:50 PM)
9.76
-0.17 (-1.71%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap279.74M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -34.81% | ||
| ROE | -44.09% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 61.91% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.04
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.73 | ||
| Quick Ratio | 4.5 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-29.2%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-18.59%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)40.99%
Revenue growth 3Y297.94%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y